Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARVE-PC: Nivolumab + Ipilimumab in AR-V7+ mCRPC
NCT02601014Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Mar 2016
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Mar 2016; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02601014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02601014.